• Nenhum resultado encontrado

Personalizing medicine for metastatic colorectal cancer: Current developments

N/A
N/A
Protected

Academic year: 2021

Share "Personalizing medicine for metastatic colorectal cancer: Current developments"

Copied!
8
0
0

Texto

Loading

Imagem

Figure 1  Exemplification of bevacizumab mechanisms of action, which  acts by inhibiting the vascular endothelial growth factor family ligands  to their receptors and thus blocking tumor angiogenesis
Table 1  Summary of the main clinical trials regarding anti-angiogenic therapies

Referências

Documentos relacionados

To determine the frequency and prognostic value of elevated microsatellite alterations at se- lected tetranucleotide repeats (EMAST) in metastatic colorectal cancer (mCRC) patients

Methods: Various resected tumor samples (33 from lymph nodes, 42 from liver, six from lung, and 68 primary tumors) were assessed via a collagen gel droplet-embedded culture

This paper examines angler opinions about the destination, angler profiles and business revenues of touristic big-game fishing in the island of San Michael, Azores

Another group of researchers evaluated the role of oral glutamine in 86 patients with metastatic colorectal cancer treated with oxaliplatin (85 mg/m² on days 1 and 15 of each

While the evidence guiding cancer-directed treatment of this disease comes from phase III trials that have mostly enrolled patients with good performance status , some patients

The present study had the aim of evaluating the combination of bolus cispla- tin, 5-fluorouracil and leucovorin (CFL) in patients with advanced (residual, metastatic or

The results of a multicentre, international (West- ern Europe, Central Europe, Eastern Europe, Cana- da, Australia, New Zealand), open-label phase III Ran- domized Controlled

Importa nesta investigação analisar o desenvolvimento da capacidade de atuação da ciberdefesa no ciberespaço nas dimensões de doutrina, organização, treino, material,